<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195337">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548470</url>
  </required_header>
  <id_info>
    <org_study_id>06I/C34-0</org_study_id>
    <nct_id>NCT00548470</nct_id>
  </id_info>
  <brief_title>Varenicline Effects In Schizophrenic Smokers</brief_title>
  <official_title>Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nathan Kline Institute for Psychiatric Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label pre-post study of the effects of clinical treatment with varenicline
      on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures
      in schizophrenic patients, and 3) effects nicotinic binding to leukocytes and DNMT1 mRNA in
      lymphocytes. Patients are assessed on subjective and objective measures of smoking ,
      selected cognitive measures, and special chemical measures, during baseline testing and
      during 8 weeks of treatment with varenicline ( 1-3 mg/day).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>self report of smoking</measure>
    <time_frame>baseline and during 8 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CO breathalyzer level</measure>
    <time_frame>baseline and during 8 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma nicotine and cotinine</measure>
    <time_frame>base and 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RBANS neuropsychological battery</measure>
    <time_frame>baseline and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Analogue of computer water maze task</measure>
    <time_frame>baseline and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Tobocco Use Disorder</condition>
  <condition>Nicotine Dependance</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline 1-3 mg/day</description>
    <other_name>Chantix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical Diagnosis of Schizophrenia or Schizoaffective Psychosis

          -  Recent History of Cigarette smoking

          -  Ages 18-65
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C Smith, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nathan Kline insitutue fo Psychiatric Research; NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manhattan Psychatirc Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S, Sershen H, Lajtha A. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2009 May;110(1-3):149-55. doi: 10.1016/j.schres.2009.02.001. Epub 2009 Feb 28.</citation>
    <PMID>19251401</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 17, 2012</lastchanged_date>
  <firstreceived_date>October 22, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nathan Kline Institute for Psychiatric Research</investigator_affiliation>
    <investigator_full_name>Robert C. Smith MD PhD</investigator_full_name>
    <investigator_title>Researchy Pasychiatrist, : Prinicipla Investigator</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>varenicline</keyword>
  <keyword>cognition</keyword>
  <keyword>cigarette smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
